We still have no “silver bullet” against myeloma—a single drug that will cure every patient every time. What is emerging instead is a new drug class, the monoclonal antibody. In this video, Dr. Joseph Mikhael suggests that, in the face of such a heterogeneous disease, more options mean more hope for patients.

Read the transcript | ow.ly/yUNoR

Dr. Joseph R. Mikhael is a hematologist/oncologist at the Mayo Clinc in Arizona, researching and treating multiple myeloma and related cancers.

View more programs featuring Dr. Mikhael | ow.ly/yUNt2

Get email alerts | ow.ly/yUNBO

Subscribe on YouTube | youtube.com/patientpower
Like on Facebook | fb.com/patientpower.info
Follow on Twitter | twitter.com/patientpower
Like on Google Plus | google.com/+patientpowerinfo

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…